How Fast Does Wegovy Start Working — and What Are the Signs It Is?

The first injection: what the first few weeks actually feel like

Semaglutide gets to work on GLP-1 receptors quickly after that first injection, and many people describe a quietening of background hunger within three to five days. The feeling is less dramatic than some expect, not a sudden switch, more a gradual lowering of the dial. You might finish a meal and realise you stopped earlier than usual, or notice that the mid-morning craving simply did not arrive.

What you are unlikely to see in week one is a significant shift on the scales. That is not a sign that the medicine is not working. The starting dose of Wegovy, 0.25 mg, is a tolerability dose: its job is to help your body adjust, not yet to drive substantial weight loss. The prescriber-led titration that follows (stepping through 0.5 mg, 1.0 mg, 1.7 mg and on toward the maintenance dose) is where the therapeutic effect accumulates. Rushing that ladder in the hope of faster results is not how the medicine is designed, and it is never something to adjust without clinical guidance. The NHS medicines information on semaglutide explains this titration sequence clearly and is worth reading alongside your patient leaflet.

If you are curious about getting the most from this early phase, our page on how to maximise weight loss on Wegovy covers the lifestyle factors (protein intake, hydration, activity) that sit alongside the medicine from day one.

When does real weight loss show up on the scales?

The decision most people are actually making in those first weeks is whether the medicine is working at all. That is understandable. For most people, measurable weight loss becomes consistent somewhere between weeks four and eight, as the dose increases and the body's response compounds. If you want a detailed breakdown of how fast Wegovy starts to work, including what to expect at each stage of the titration, our dedicated page covers the timeline in full.

The STEP 1 trial, published in the New England Journal of Medicine, gives the clearest population-level picture: 68 weeks at the 2.4 mg maintenance dose produced an average body-weight reduction of around 15%. That average conceals a wide range, some participants lost considerably more, some less. The MHRA's approval in April 2026 of the 7.2 mg single-dose pen has since added a higher maintenance option, with trial data showing around 20.7% average weight loss over 72 weeks, though that is only relevant once a prescriber decides you are a candidate for it.

Timing matters in everyday life too. If your first pen arrives the week before a holiday, or you start in a month when routine is disrupted, the early weeks may look different from someone who starts on a calm Monday with their fridge stocked and their sleep sorted. That does not change the medicine's mechanism, it just means the context around weight is noisier. Give it a fair run before drawing conclusions.

For a fuller look at the Wegovy treatment overview, including how the injection is taken and what to expect through the dose stages, our dedicated page walks through the whole picture.

Factors that shape your personal timeline

Several things influence how quickly an individual responds, and understanding them helps set realistic expectations rather than chasing an average that may not apply to you.

Dose level is the biggest factor. At 0.25 mg the effect on appetite is present but modest; at 2.4 mg or 7.2 mg it is substantially stronger. This is why patience through the titration period matters so much. Starting dose, pace of increase and the maintenance dose reached are all determined by your prescriber based on how you tolerate each step, not by how much you want to lose or how quickly.

Individual biology plays a clear role too. Gut motility, baseline insulin sensitivity, prior dieting history and the proportion of weight carried as visceral fat can all affect how the medicine's appetite and metabolic signals translate into scale weight. Clinical guidance from NICE's appraisal of semaglutide (TA875) notes that if less than 5% weight loss is achieved after six months at the maintenance dose, continuing should be reviewed, a useful benchmark for your own monitoring.

Lifestyle factors compound the medicine's effect rather than substitute for it. Protein adequacy, resistance activity and consistent sleep all support lean-mass retention while fat loss occurs. These are covered in more detail on our page about how long Wegovy takes to work, which looks at the same question from the perspective of expected milestones through treatment.

What to do if progress feels slower than expected

If you reach week eight or ten without any meaningful change, the right move is to talk to your prescriber, not to stop, not to increase your dose independently, and not to assume the medicine has failed. There are several possible explanations: the dose may still be in the tolerability range, dietary intake may have adjusted upward to compensate for the appetite change, or there may be an individual factor worth exploring. Our page on how long it takes for Wegovy to start working can help you understand whether your experience falls within the normal range before raising it with your prescriber.

At nume, every repeat order goes through a fresh clinical review, so there is a natural point to raise this. Our clinical team takes slow response seriously and can assess whether the current dose or the overall plan needs adjustment. That conversation is part of the service, not an add-on.

If you are still weighing up whether semaglutide or another licensed treatment is the right fit, our weight-loss treatment overview lays out the options available through a UK private prescription. And if cost context is on your mind, our Wegovy price page explains what is included in a private prescription service and what to look for when comparing providers.

When you are ready to find out whether Wegovy is clinically appropriate for you, you can check your eligibility with a free consultation, reviewed the same day by a named GPhC-registered prescriber.